Skip to main content
SpringerLink
Log in

Cytarabin (z.B. Alexan®, Udicil®)

  • Chapter
Book cover Paravasation von Zytostatika

  • 732 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Primärliteratur

  1. Slevin ML, Piall EM, Aherne GW, et al: Subcutaneous infusion of cytosine arabinoside: a practical alternative to intravenous infusion. Cancer Chemother Pharmacol 10: 112–114, 1983.

    Article  PubMed  CAS  Google Scholar 

  2. Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.

    PubMed  CAS  Google Scholar 

Sekundärliteratur

  1. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    PubMed  CAS  Google Scholar 

  2. Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guidelines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.

    PubMed  CAS  Google Scholar 

  3. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  4. Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.

    Google Scholar 

  5. Pharmacia & Upjohn, persönliche Mitteilung, November 1998.

    Google Scholar 

  6. Gain M, Melzer S, Meyer-Jürshof A, et al: Cytarabin: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 3: 42, 1998.

    Google Scholar 

  7. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6. Auflage: 1–17, 1999.

    Google Scholar 

  8. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  9. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  10. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: A42–44, 1997.

    Google Scholar 

  11. Fachinformation Alexan® (Österreich), Ebewe, Juni 2003.

    Google Scholar 

  12. Dorr RT, Von Hoff DD: Drug monographs: cytarabine. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 332–340, 1994.

    Google Scholar 

  13. Barth J: Paravasate und deren Behandlung. In: Barth J (Hrsg) Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, Kap. VI-3: 1–9, 2000.

    Google Scholar 

  14. Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.

    Article  PubMed  CAS  Google Scholar 

  15. Krämer I, Stützle M: Zytostatika-Paravasation — Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.

    Google Scholar 

  16. Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.

    Article  PubMed  CAS  Google Scholar 

  17. Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.

    Article  PubMed  CAS  Google Scholar 

Zusätzlich wurden folgende Publikationen zum Literaturstudium herangezogen

  1. Fenchel K, Karthaus M: Zytostatika-Paravasate — gibt es neue Empfehlungen zum therapeutischen Vorgehen? Wien Med Wochenschr 151: 44–46, 2001.

    PubMed  CAS  Google Scholar 

  2. Rauh J, Pluntke S, Müller C: Paravenöse Zytostatikainjektion: Prophylaxe und Sofortmaßnahmen im Notfall. MMW Fortschr Med 146: 682–686, 2004.

    Google Scholar 

  3. Schrijvers DL: Extravasation: a dreaded complication of chemotherapy. Ann Oncol 14: iii26–iii30, 2003.

    PubMed  Google Scholar 

Download references

Authors
  1. Sabine Wassertheurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag/Wien

About this chapter

Cite this chapter

Wassertheurer, S. (2006). Cytarabin (z.B. Alexan®, Udicil®). In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/3-211-36215-0_23

Download citation

  • DOI: https://doi.org/10.1007/3-211-36215-0_23

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25225-3

  • Online ISBN: 978-3-211-36215-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation